U.S. pharma big copyright scrapped two experimental weight loss capsules past year—a once-each day tablet, lotiglipron, as a consequence of elevated liver enzymes and also a 2 times-daily tablet, danuglipron, resulting from sturdy Uncomfortable side effects—but CEO Albert Bourla has reported the company is determined to “play and earn” with